Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Up to $10.40

Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) gapped up prior to trading on Wednesday . The stock had previously closed at $10.40, but opened at $10.78. Gyre Therapeutics shares last traded at $10.25, with a volume of 2,428 shares changing hands.

Gyre Therapeutics Trading Up 0.8 %

The business’s fifty day moving average price is $12.16 and its 200 day moving average price is $14.46.

Insider Buying and Selling

In related news, Director Nassim Usman sold 3,452 shares of the firm’s stock in a transaction that occurred on Friday, June 28th. The stock was sold at an average price of $12.00, for a total transaction of $41,424.00. Following the completion of the transaction, the director now owns 1,636 shares in the company, valued at approximately $19,632. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 2.92% of the company’s stock.

Institutional Investors Weigh In On Gyre Therapeutics

Several large investors have recently made changes to their positions in the company. Renaissance Technologies LLC bought a new stake in Gyre Therapeutics during the 2nd quarter worth approximately $166,000. Rhumbline Advisers bought a new stake in shares of Gyre Therapeutics during the second quarter worth $123,000. Bank of New York Mellon Corp bought a new stake in shares of Gyre Therapeutics during the second quarter worth $218,000. Finally, WINTON GROUP Ltd acquired a new stake in shares of Gyre Therapeutics in the second quarter valued at $220,000. Institutional investors own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.